2 Einträge |
Seite 1 / 1
![]() |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
Therapeutic management of metastatic breast cancer across Europe: European observatory and survey (EOS). |
Krzemieniecki K, Antolín Novoa S, Gozy M, Schumacher C, Steger GG, Carteni' G, Bird BR, Albuisson E, Barnadas A, Batist G, De Mouzon J, Erdkamp F, Leonard RC, Lueck H, Namer M, Venturini M, Ronga P, Maumus-Robert S, Aapro MS |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jan 1. pii: 10.1200/jco.2011.29.15_suppl.e11556 |
PMID: 28021699 |
2 Einträge |
Seite 1 / 1
![]() |